AstraZeneca’s evolution from traditional paper access request forms to an automated system.
Founded in 1999, AstraZeneca is a multinational pharmaceutical and biotechnology company, headquartered in Cambridge, England. Aside from England, AstraZeneca has primary locations in Gothenburg, Sweden and Gaithersburg, Maryland.
AstraZeneca has a portfolio of products for major diseases in areas including oncology, cardiovascular, gastrointestinal, infection, neuroscience, respiratory, and inflammation.
Over the last 13 years, AstraZeneca’s clearance procedure has been almost entirely physical. This necessitated hand signatures, meaning individual requesters had to physically seek out clearance owners to review and sign off on their individual access requests. Additionally, each request’s paper trail created by this process had to be filed away in physical cabinets.
AstraZeneca’s sustainability commitments and best practices required the ongoing management of their environmental impact across all their activities and products. In 2015, to evolve their traditional paper business access request forms to a semi-electronic system, several of AstraZeneca’s sites implemented DocuSign.
This system improved on the paper method but still came with a host of issues. DocuSign had no logic for routing requests and approvals and required AstraZeneca to hire additional resources to move requests through the clearance process. DocuSign also charged fees for cloud storage and for every request opened, quickly adding to costs as many requests were restarted or automatically opened from refreshing browser pages.
C•CURE Access Management Workflow updated the physical clearance process by simplifying how requests could be accepted or rejected. When a rejection is made, a user is now only required to make a note of why the request was rejected, eliminating the need for follow-ups. In Q4 2020, AstraZeneca soft launched C•CURE Access Management Workflow before rolling the process out to all global locations across the enterprise system. Between Q4 2020 and Q3 2022, access request submissions through the C•CURE Portal increased from 6 to 642.
With C•CURE Access Management Workflow, AstraZeneca found a way to move past a laborious physical clearance process and into a modernized, simplified electronic one. By upgrading this process, AstraZeneca’s security teams are empowered to focus on keeping their areas safe and compliant.